Introduction

Approximately 19% of congenital heart defects involve some degree of Right Ventricular Outflow Tract (RVOT) obstruction. These obstructions can be at the level of the pulmonary valve, infundibulum, proximal branches, or distal branches of the pulmonary artery. The severity of the clinical presentation is usually dependent on the severity of RVOT obstruction and can range from an asymptomatic infant to one that is severely cyanotic.

Many of these cases of RVOT obstruction mentioned above have associated Coronary Artery (CA) anomalies, known as prepulmonary coronary arteries. In this anomaly the coronary courses anterior to the pulmonary artery or RVOT. These prepulmonary coronary artery anomalies are associated with one or more cardiac malformations and alter surgical management if present.

Key Words

Right Ventricular Outflow Tract Obstruction, Cardiac Computed Tomography Angiography, Coronary Artery Anomalies.

Surgical-Relevant Coronary Artery Anomalies Diagnosed by Cardiac Computed Tomographic Angiography in Infants and Children with Right Ventricular Outflow Tract Obstruction

By Erin E. Birmingham, MD; Abhineet M. Sharma, MD; Salil Ginde, MD; and Randy R. Richardson, MD

Many of these cases of RVOT obstruction mentioned above have associated Coronary Artery (CA) anomalies, known as prepulmonary coronary arteries. In this anomaly the coronary courses anterior to the pulmonary artery or RVOT. These prepulmonary coronary artery anomalies are associated with one or more cardiac malformations and alter surgical management if present.
We are committed to the lifetime management of congenital heart disease.

Transcatheter and Surgical Heart Valves
RVOT Conduits
Ablation Technologies
ICDs
Oxygenators and Filters
Cannulae
Pacemakers
Pulse Oximetry Monitoring for CCHD Screening
3rd Generation PFO, ASD, and PDA Occluders*
Cerebral/Somatic Monitoring

*These products are not available in the US.

Medtronic
Minneapolis, MN 55432-5604
Toll-free: 1 (800) 328-2518

©2015 Medtronic.
Cardiac computed tomography with multidetector-row computed technology is a novel modality that can be used as a “one-stop shop” to non-invasively evaluate the coronary arteries, cardiac morphology, and cardiac function. It is also useful to assess coronary morphology and patency prior to and following surgical intervention for Congenital Heart Disease. Here, we compiled the largest number of coronary artery anomalies in RVOT obstruction evaluated by Coronary Computed Tomography Angiography (CCTA) in one study. Our study aimed to demonstrate the utility of CCTA as an imaging modality for the diagnosis of CA anomalies in cases of RVOT obstruction and CHD.

Materials and Methods

We retrospectively reviewed 220 standard preoperative CCTA exams in infants and children performed over the period between 03/28/2005 and 09/18/2010 at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. All images were obtained as a part of preoperative protocol. Of the 220 exams, we found 67 patients with RVOT obstruction. Of the 67 patients, there were a total of 37 males and 30 females, ranging in age from 1 day to 15 years (Mean: 312 days; Median: 7 days). CCTA was performed with a 64-slice multidetector CT, with prospective EKG gating, followed by three-dimensional reformations. Our institution’s current technique for CTA with 3D reconstruction uses prospective gating with padding to capture functional source data with less radiation. Images were captured from the thoracic inlet to the upper abdominal cavity. The clinically indicated 3D data set was acquired only once and was also used to assess the quality of the coronary images.

A Kruskal-Wallis analysis was used to see if there was a significant difference in the frequency of CA in the specific subtypes of RVOT. A Chi-squared test was utilized to see if there was a statistically significant difference in the frequency of CA anomalies in our RVOT population when compared to the overall population based on two studies.

The data analysis was approved by the institutional review board at St. Joseph’s Hospital and Medical Center. A waiver for informed consent was obtained. Literature was accessed through the PubMed search database using the phrases right ventricular outflow tract obstruction, coronary artery anomalies, cardiac computed tomographic angiography, and post-operative complications of Congenital Heart Disease.

No financial support was provided for data collection and analysis of manuscript preparation.

Results

Of the 220 CCTA exams performed, there were 67 patients with RVOT obstruction. These patients were grouped into 6 categories based on congenital heart anomaly (Table 1). Twenty-six of 67 patients were found to have Tetralogy of Fallot (TOF) and pulmonic stenosis (Group A). Fifteen patients had TOF and pulmonic atresia (Group B). Five patients had TOF with absent pulmonary valve (Group C). Four patients had isolated pulmonic stenosis (Group D). Seven patients had isolated pulmonic atresia (Group E) and pulmonic atresia and pulmonic stenosis (Group F).

<table>
<thead>
<tr>
<th>Type of RVOT Obstruction</th>
<th>Percentage of Patients in Study Cohort (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A: Tetralogy of Fallot and Pulmonic Stenosis</td>
<td>38.8% (26)</td>
</tr>
<tr>
<td>Group B: TOF and Pulmonary Atresia</td>
<td>22.4% (15)</td>
</tr>
<tr>
<td>Group C: TOF with Absent Pulmonary Valve</td>
<td>7.5% (5)</td>
</tr>
<tr>
<td>Group D: Isolated Pulmonic Stenosis</td>
<td>6.0% (4)</td>
</tr>
<tr>
<td>Group E: Isolated Pulmonary Atresia</td>
<td>10.4% (7)</td>
</tr>
<tr>
<td>Group F: Double-Outlet Right Ventricle (DORV)</td>
<td>15.0% (10)</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>67</td>
</tr>
</tbody>
</table>
E). Ten patients had different forms of Double Outlet Right Ventricle (DORV) (Group F). Fourteen of these 67 patients (20.9%) were found to have surgically relevant CA anomalies (Table 2). The most common CA anomaly seen with RVOT obstruction was the prominent conal branch, which made up 57% of cases. The prominent conal branch was seen most commonly in Tetralogy of Fallot with pulmonic stenosis. A Kruskal-Wallis analysis showed that there was no statistically significant association between RVOT subtype and frequency of coronary artery lesion ($H=1.86$, $df = 4$, $p = 0.76$). When compared to the incidence in the general population, the incidence of CA anomaly was higher in the RVOT Obstruction group when compared to studies done in the general population ($X^2 = 26.12$, $p = 0.0001$).

**Discussion**

Our results confirm that prominent coronary artery anomalies occur at a higher frequency in cases of RVOT obstruction when compared to the general population, with up to 20.6% of patients with RVOT obstruction having a CA anomaly. Additionally, our study found that CA anomalies do not occur more frequently in a specific type of RVOT obstruction, making it difficult to predict if surgeons might encounter a CA anomaly during a procedure. Our study shows that CCTA can be used to effectively diagnose various CA anomalies preoperatively and aid in operative management. For example, Figure 6 shows a case of a pre-pulmonary LAD artery that was found prior to surgery and altered surgical repair. Post-operative pictures show that the anomalous coronary artery was preserved without any post-operative complications. Hence, CA anomalies that would complicate the initial routine repair may require a different surgical approach.

Routine bedside echocardiography remains the first-line imaging modality to visualize the infant heart and coronary arteries due to its low cost, widespread availability, portability, ease of use, and excellent temporal-spatial resolution. As a result echocardiography reduces the need for diagnostic cardiac catheterization and angiography in most patients. However, the diagnostic utility of echocardiography markedly diminishes with the growth of patients and after surgical procedures through median sternotomy because acoustic windows become progressively more limited.

Previous studies have also reported the use of magnetic resonance imaging to diagnose various coronary artery anomalies in infants and children. Tangcharoen et al evaluated the feasibility and accuracy of magnetic resonance (MR) coronary angiography for the detection of CA anomalies in infants and children by using surgical findings as a
Cardiac MRI offers several favorable characteristics in comparison with the conventional imaging modalities, including: good tissue characterization, being operator independent, capacity for three-dimensional imaging, accurate flow measurements, ventricular function analysis, freely-selectable imaging planes, and lack of ionizing radiation. However, coronary MR angiography may be limited by irregular respiratory and cardiac rhythm, difficulty in delineating small CA's, and relatively long examination time. A comprehensive cardiac MRI investigation requires approximately 30 to 60 minutes with the patient in a still position in an uncomfortable environment; therefore, children under the age of 12 will commonly require anesthesia or conscious sedation. As a result, it is often difficult to identify the complete coronary artery anatomy in most infants on MR, while CCTA can be a more reliable imaging modality in this age group.

CCTA is currently not the major modality for evaluating CA anomalies in Congenital Heart Disease, in particular RVOT obstruction. We found only one other study looking at coronary artery imaging with multislice CCTA. Hyun et al describes current multislice techniques for coronary artery imaging. The review was based on approximately 1,200 cardiac CT examinations over a period of 7 years. Hyun recommended that high temporal resolution, high z-axis spatial resolution, and effective suppression of cardiac motion are key CT parameters for visibility of CA's. Exposure to radiation remains a compelling concern when using CCTA; however, employing certain factors can minimize this risk. The imaging in our study was obtained using multi-detector row technology (64 multi-slice CT), to increase resolution and shorten the time spent imaging – allowing for

![Figure 3. LCA in front of the RVOT in a case of Double-Outlet Right Ventricle. Color-coded 3D images. a. Anterior view of the entire heart. b. Anterior view of aorta (red) with coronary arteries (neutral). Both outflow tracts come off the morphologic right ventricle which is on the left and is enlarged (violet). There is a single coronary coming off the left coronary sinus. The morphologic left coronary artery which goes to the right goes between the right and left ventricular outflow tracts and is consistent with a malignant type off coronary artery course. There is an accessory left anterior descending artery coming of the morphologic right coronary artery, which is on the left and courses anterior to the right ventricle. This patient also has evidence of total anomalous pulmonary venous return, L-type Transverse Position of the Great Arteries, and heterotaxy with bilateral right-sidedness with thoracic situs inversus.](image)

![Figure 4. LCA in front of the RVOT in a case of dysplastic pulmonary valve and pulmonic stenosis: Color-coded 3D images. Anterior views (a and c) and posterior views (b) showing the aorta (red), pulmonary arteries (blue), left ventricle (salmon), right ventricle (violet), right atrium and SVC (light blue) and coronary arteries (neutral). The right coronary artery arises from the LAD (arrow) and courses anterior to the right ventricular outflow tract to the right atrioventricular groove. The left coronary artery originates from the left coronary sinus and is dilated (yellow arrow). Dysplastic pulmonary valves were found with stenosis of the pulmonary artery and right ventricular hypertrophy.](image)
less exposure to radiation. With multi-detector row CT, volumes of ionic IV contrast as small as 2 mL/kg allow successful contrast enhancement for CT angiography. Multislice CT has led to the ability to perform high-resolution scans gated to the cardiac cycle, known as ECG-synchronized CT. These scans can be retrospectively gated or prospectively triggered. Strict breath-holding ability is necessary for retrospective ECG-gated CT in young children. Thus, prospective ECG-triggered CT is a viable option for free-breathing young children because the scan technique is less affected by respiratory motion. The use of ECG prospective gating in multislice CT scan allows a further reduction of the radiation exposure, thanks to the acquisition of images limited to 70-80% of the R-R interval. In addition to reducing exposure to radiation, Hyun et al found that visibility of the coronary arteries by CT has markedly improved with prospectively ECG-synchronized CT.

Due to the much shorter imaging time when compared to MR, the sedation rate for young children undergoing multidetector row CT is less than 5% [20]. Many of the studies in the literature support the idea that MR image quality and sharpness increased significantly with age and slower heart rates but did not perform as well in patients younger than four. However, CCTA image quality is independent of heart rates, which is very important in neonates with heart rates up to 160-180 beats per minute. Both Hyun et al and our study support the fact that high temporal resolution and ECG-synchronized data with CCTA improves visibility of the coronary arteries and congenital heart defects beyond most other imaging studies.

This is the first study of its kind, investigating the use of CCTA to diagnose coronary artery anomalies in RVOT obstruction. Our intent was to establish a consistent imaging modality for the diagnosis of these surgically-relevant CA anomalies when echocardiography is equivocal and MRI is not feasible. This would allow surgeons to establish early and primary reparative surgery while maintaining the inherent CA anatomy. We have shown that CCTA with 3D reconstruction is an advanced, safe, and reliable imaging modality that provides accurate diagnosis even when echocardiographic data is equivocal. The high-resolution 3D reconstructions are essential in the identification of the complex cardiac anatomy seen in these patients, and is necessary for preoperative planning, modified surgeries, and overall management of these patients.

Conclusion

Many cases of RVOT obstruction have associated coronary artery (CA) anomalies that can go undiagnosed prior to surgery. Multidetector cardiac CTA with EKG gating is a safe and feasible tool for the detection of surgically-relevant CA anomalies in patients with RVOT stenosis or obstruction. Abnormal CA anatomy must be considered prior to surgery in any infant with CHD and intracardiac defects. CCTA is very useful adjunct imaging modality for preoperative planning and overall management, when Echocardiographic imaging is unclear.

Limitations

Limitations to this study include the retrospective study design and that there was no direct comparison between CCTA and other imaging modalities.
imaging modalities. In addition, it is unclear if the coronary anomalies seen on CT imaging were confirmed at the time of surgery.

Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent was not required.

References


**Biographical Sketch**

Erin Birmingham, MD is currently in her second year of pediatrics residency at Children’s Hospital of Wisconsin/Medical College of Wisconsin. She obtained her medical degree from Creighton University School of Medicine.

**Corresponding Author**

Erin E. Birmingham, MD
Children’s Hospital of Wisconsin
Medical College of Wisconsin
8701 West Watertown Plank Rd.
Wauwatosa, WI 53226 USA

Mailing Address:
Medical Education Office
Children’s Corporate Center
999 N. 92nd St., Suite 730
Milwaukee, WI 53226 USA
Phone: 414.266.6800; Fax: 414.337.7068
ebirmingham@mcw.edu

Abhineet M. Sharma, MD
Children’s Hospital of Wisconsin
Medical College of Wisconsin
8701 West Watertown Plank Rd.
Wauwatosa, WI 53226 USA

Salil Ginde, MD
Children’s Hospital of Wisconsin
Medical College of Wisconsin
8701 West Watertown Plank Rd.
Wauwatosa, WI 53226 USA

Randy R. Richardson, MD
Department of Radiology
St. Joseph’s Hospital and Medical Center
350 West Thomas Rd.
Phoenix, AZ 85013 USA

---

**Pediatric Cardiac Intensivist Faculty Positions**

The Divisions of Pediatric Critical Care Medicine and Pediatric Cardiology in the Department of Pediatrics at Washington University School of Medicine seek applicants for faculty positions in the Cardiac Intensive Care Unit (CICU) at Saint Louis Children’s Hospital (SLCH). The positions include an appointment at appropriate rank in the Washington University School of Medicine. Successful candidates will serve on a team consisting of eleven attending cardiac intensivists and will also provide consultation in the neonatal and pediatric intensive care units at SLCH. Participation in house staff and fellow education as well as clinical, translational or laboratory-based investigations will be expected. Extensive opportunities exist for scholarly collaborations with investigators at the School of Medicine and other departments throughout Washington University.

The Saint Louis Children’s and Washington University Heart Center is a highly ranked pediatric cardiac program and includes 3 pediatric cardiothoracic surgeons, 18 pediatric cardiologists, 10 pediatric cardiac intensivists (1 dual boarded in Critical Care and Cardiology), 5 CCM boarded with advanced training in CICU, 2 Cardiology boarded with advanced training in CICU, and 2 anesthesiologists with advanced training in CICU. In our Cardiac Intensive Care Unit (CICU), we provide clinical care, teach, and perform clinical, translational and basic research. See the following links for details on the Divisions of Pediatric Cardiac Critical Care Medicine, Pediatric Cardiology and the section of Pediatric Cardiac Intensive Care Surgery:

- [http://pediatrics.wustl.edu/criticalcare/Home.aspx](http://pediatrics.wustl.edu/criticalcare/Home.aspx)
- [http://pediatrics.wustl.edu/cardiology/Home.aspx](http://pediatrics.wustl.edu/cardiology/Home.aspx)
- [http://cardiothoracicsurgery.wustl.edu/Pediatric](http://cardiothoracicsurgery.wustl.edu/Pediatric)

Our CICU is a state-of-the-art, 16-bed, dedicated unit that provides all forms of cardiovascular intensive care for children and adults with congenital and acquired cardiovascular diseases. Approximately 400 patients are admitted to the CICU per year, with 60% surgical admissions. Patients range in age from premature neonates to adults, and patient complexity and acuity are amongst the highest in the nation. A full range of clinical services is available, including mechanical circulatory support for heart failure patients with ventricular assist devices (Thoratec, Berlin Heart, HeartMate II, HeartWare), the paracorporeal lung assist device system (Novalung and Quadrox oxygenators) and ECMO. We have an internationally renowned heart failure/transplant program and perform approximately 20 heart transplants each year. Critically ill pre- and post- transplant patients are managed in the CICU.

Please visit our website at [http://hr.wustl.edu](http://hr.wustl.edu) to view a summary of benefits.

The ideal candidate should be board certified/eligible in Pediatric Critical Care Medicine, Pediatric Cardiology, or Pediatric Anesthesia and have completed advanced training in pediatric cardiovascular intensive care (either via dual fellowships in pediatric cardiology and critical care medicine or via completion of an advanced cardiovascular intensive care fellowship).

**Interested candidates should send a letter of intent and curriculum vitae to:**

Avihu Z. Gazit, M.D., Medical Director,
Cardiac Intensive Care,
Washington University in Saint Louis,
1 Children’s Place, Campus Box 8116,
Saint Louis, MO 63110. Email: gazit_a@kids.wustl.edu

Washington University is an equal opportunity employer and is committed to increasing the diversity of its faculty. It welcomes nominations of and applications from women and members of minority groups, as well as others who would bring additional dimensions to the university’s research, teaching and clinical missions. All qualified applicants will receive consideration for employment without regard to sex, race, ethnicity, protected veteran, or disability status.
MELODY TPV DELAYS CONDUIT REPLACEMENT

98%
Patients at 2 years

91%
Patients at 5 years

Data from US IDE Study
Important Labeling Information for United States

Indications: The Melody TPV is indicated for use as an adjunct to surgery in the management of pediatric and adult patients with the following clinical conditions:

- Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted AND
- Dysfunctional RVOT conduits with a clinical indication for intervention, AND:
  - regurgitation: ≥ moderate regurgitation, AND/OR
  - stenosis: mean RVOT gradient ≥ 35 mm Hg

Contraindications: None known.

Warnings/Precautions/Side Effects

DO NOT implant in the aortic or mitral position. Preclinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.

DO NOT use if patient’s anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.

DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.

Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.

To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.

The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.

If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, blistering, or peeling of skin, pain, swelling, or bruising at the catheterization site.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvar leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

*The term “stent fracture” refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions For Use provided with the product.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.

Melody is a registered trademark of Medtronic.

Medical City Children’s Hospital has an unwavering focus on patient care and offers world-renowned excellence in comprehensive pediatric services. Since 1996, our specialists haven’t let anything distract them from serving children. As a result, we’ve helped thousands of children from more than 75 countries. We are a comprehensive children’s hospital with specialists in virtually every pediatric subspecialty. Medical City is the only facility in North Texas where fetal diagnosis, maternal, neonatal and pediatric transport, high risk delivery stabilization in the NICU, corrective surgery, state of the art postoperative monitoring and care and long term follow-up of patients with complex congenital heart disease can all be delivered under one roof.

The Congenital Heart Surgery Unit (CHSU) accommodates around 400 children annually who undergo heart operations performed by Dr. Eric Mendeloff. 30% of our cases are neonates and 58% are under the age of 2 years. Cases range in complexity from palliation of hypoplastic left heart syndrome to closure of atrial and ventricular septal defects. Highly specialized care in the CHSU is provided by subspeciality-trained physicians and an excellent group of long term nurses and respiratory therapists. This focus on pediatric cardiac critical care has resulted in superlative patient outcomes that exceed national norms. The heart program’s success has attracted referrals from across the country. With the addition of a second Congenital Heart Surgeon to our already robust program, we anticipate growth that will require a sixth member for our CICU team in addition to our need for a Medical Director of the Unit. Preferred candidate for the director level position will possess leadership attributes with evidenced experience, along with a strong clinical skill set.

All candidates are preferred to be BC/BE in Pediatric Cardiology and Pediatric Critical Care or boarded in one of these with additional training in Pediatric Cardiac Critical Care. Those with certification in one discipline and solid experience in the alternate subspecialty should also apply. Positions are employed and offer a competitive salary and excellent benefits packet.

Our hospital has immense current capabilities and is positioned to grow.

Kathy Kyer
National Director of Pediatric Subspecialty Recruitment
Kathleen.Kyer@HCAHealthcare.com
937.235.5890
The 7th World Congress of Pediatric Cardiology & Cardiac Surgery Has Changed Date and Venue: July 16th-21st, 2017, Barcelona, Spain

The Organizing Committee has announced the 7th World Congress of Pediatric Cardiology and Cardiac Surgery (WCPCCS), will take place on July 16th - 21st, 2017, in the Centre Convencions Internacional de Barcelona (CCIB), Barcelona, Spain.

“The 7th World Congress of Pediatric Cardiology & Cardiac Surgery has changed date and venue: July 16th-21st, 2017, Barcelona, Spain”

The aim of WCPCCS is to bring together all professionals involved in the care of Pediatric Heart Disease and Congenital Heart Disease of all ages, from the fetus to the aged. The Congress will provide a unique opportunity to meet the leaders of specialties worldwide; to learn about the latest innovations and the results of procedures; and to contribute to the discussions, debates and plenary sessions with renowned speakers.

The central philosophy of the Congress is “bridging together” all major specialties in the field. Accordingly, the scientific program is carefully planned to address all interests and expertise with concentration streams on pediatric cardiology; pediatric cardiac surgery; adult congenital heart diseases; anesthesia; intensive care and nursing.

We are excited to offer the scientific and cultural feast of a lifetime to one of the most refined crowds in the profession, in one the most welcoming, inimitably exciting venues of the world. For more information visit: www.wcpccs2017.org.

Study Identifies a Developmental Cause of Cardiac Hypertrophy - New Findings Provide Important Insights into a Leading Cause of Heart Failure

Newswise – Investigators at Beth Israel Deaconess Medical Center (BIDMC) have identified a developmental cause of adult-onset cardiac hypertrophy, a dangerous thickening of the heart muscle that can lead to heart failure and death. Reported July 7th online in The Journal of Clinical Investigation, the new findings could lead to targeted therapies for this condition.

“Genetic mutations that alter signaling pathways involved in cardiac development have been implicated in approximately 30% of birth defects associated with Congenital Heart Disease,” explained Maria Kontaridis, PhD, Interim Director of Basic Cardiovascular Research in the CardioVascular Institute at BIDMC and Assistant Professor of Medicine at Harvard Medical School. “In this study, we wanted to determine whether these same genetic mutations can also lead to the development of cardiac hypertrophy in adults.”

Work in the Kontaridis lab focuses on a cluster of genetic diseases known as RASopathies, which impact the Ras/MAPK cell signaling pathway and affect the growth and differentiation of cells. One of these diseases, Noonan Syndrome with Multiple Lentigines (NSML), is a rare condition caused primarily by mutations in the gene PTPN11. NSML has multiple phenotypic characteristics, including short stature, growth retardation, and craniofacial abnormalities, but the most prevalent defects affect the heart, the most common of which is cardiac hypertrophy.

By creating NSML mice that expressed the PTPN11 mutation, the scientists were able to gain important insights into what causes Congenital Heart Disease and how these defects lead to hypertrophy.

“In this study, we observed that there were significant developmental abnormalities in hearts affected by NSML,” explained Kontaridis. “We wanted to figure out if the adult-onset cardiac hypertrophy we observed might be caused by abnormal regulation of one or more of the critical cell populations necessary for growth and development of the heart.”

Cardiac development consists of a sequential order of events that are controlled by intercellular communication between three critical cell populations, which become the heart’s endocardium, myocardium and neural crest regions. Carefully orchestrated cross-talk between these cell populations culminates in a fully functional heart. Multiple cell signaling pathways regulate these complex developmental events, but when these pathways are disrupted, communication breaks down, leading to various cardiac defects.

“Our experiments unexpectedly revealed that hypertrophy was caused by abnormal cell signaling mechanisms originating from developing endocardium—not the myocardium, as had been long assumed,” said Kontaridis.

Experiments with mice expressing the genetic mutation only in the cells destined to give rise to the endocardium showed that as these mice aged, they developed hypertrophic cardiomyopathy. Mice with mutations in the myocardial- or neural crest- regions did not show signs of associated hypertrophy, definitively identifying the endocardium as the source of hypertrophy in NSML.

“This was the first time we were able to trace the cause of an adult-onset hypertrophic disease to abnormal development, and...
specifically to a disruption in critical endocardial to myocardial cell ‘crosstalk,’” explained Kontaridis.

“These findings not only tell us that there are developmental components to NSML that we can potentially target therapeutically, but also suggest that we can start to think about what the signaling differences may be between this RASopathy and other RASopathy disorders that cause similar, but different cardiac defects,” said Kontaridis. “More important, we can consider these same approaches when thinking about treating other, more common, congenital hypertrophy disorders.”

Study coauthors include: BIDMC investigators Jessica Lauriol (first author), Janel R. Cabrera, Ashbeel Roy, Kimberly Keith, Sara M. Hough, Federico Damilano, Bonnie Wang and Saumya Das; Roderick Bronson of Harvard Medical School; and Gabriel C. Segarra, Meaghan E. Flessa, Lauren E. Miller and Kyu-Ho Lee of the Medical University of South Carolina.

This work was supported by grants from the National Institutes of Health (R01-HL102368, R01-HL114775, R1-HL122238, T32HL073734) and support from the Children’s Cardiomyopathy Foundation and the American Heart Association.

For more information, visit www.bidmc.org.

**Correction to August 2016 Issue:**

The August 2016 article, “Double-Orifice Tricuspid Valve: Case Report with a Review,” by DR Hakim Irfan Showkat, MBBC, MD; Rekha Mishra, MD; Vinod Sharma, MD, DM; Lokesh Chandra Gupta, MD, DM; and Sadaf Anwar, PGDCC, had some missing author information. It is correct above, and has been corrected on the PDF versions, which can be found on page 7 for both the North American and International editions at:

- North American Edition
  www.congenitalcardiologytoday.com/index_files/CCT-AUG16-NA.pdf
- International Edition
  www.congenitalcardiologytoday.com/index_files/CCT-AUG16-INT.pdf

**CONGENITAL CARDIOLOGY TODAY**

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share? Submit your manuscript to: RichardK@CCT.bz

**Featuring:**

Barry Maron, MD
Martin Maron, MD
Harry Lauer, MD

October 21-22, 2016
Courtyard Downtown Marriott
Boston, MA
www.4hcm.org

**Carolyn Ho, MD**
Lisa Salberg
N.A. Mark Estes, MD
Mark Link, MD
In July, 1995 during my first month of Pediatric Cardiology fellowship at the University of California San Diego (UCSD), I took care of a patient with Jacobsen Syndrome (JS), a rare chromosomal disorder caused by deletions in the long arm of chromosome 11. My interest in this syndrome was heightened by the possibility of identifying a novel gene for left-sided obstructive lesions, including HLHS (Hypoplastic Left Heart Syndrome), which we subsequently discovered occurs at a higher frequency in JS than for any other known human genetic syndrome. Fast forward to June, 2016: serving as the Chief Medical Advisor for the past 15 years for the 11q Research and Resource Group (www.11qusa.org), a support group for patients and their families with JS, I worked with the group’s President, Linzee Carroll (mother of two children with JS), to organize the 10th Biennial International Conference held in San Diego, June 26th-30th. Fifty-one families and 15 invited faculty from nine countries representing four continents, gathered for the four-day conference. Just over half of the families were attending for the first time.

While my initial interest was and continues to be in the genetic basis of HLHS and other congenital heart defects that occur in JS, through the encouragement of the families I have established collaborations that have focused on many of the other major causes of morbidity and mortality in JS including: a congenital platelet disorder, varying degrees of intellectual disability, behavioral problems including autism and ADHD (Attention Deficit Hyperactivity Disorder), and life-threatening immunodeficiencies.

Day One of the conference began with the keynote speaker, Ms. Peyton Goddard (www.peytongoddard.com), who depicted her struggles as a severely autistic and non-verbal child. She described how using facilitated communication allowed her to overcome her limitations, as well as the discrimination, abuses and biases of others to accomplish, among her many remarkable achievements, graduating valedictorian from her college. The remainder of the day included talks on several of the recently-identified major medical issues including immunodeficiency and brain hemorrhages. The afternoon featured a

Master Class in Congenital Cardiac Morphology
With world renowned cardiac pathologist Professor Robert Anderson, MD, FRCPath
Sept. 28 to 30, 2016 • Children’s Hospital of Pittsburgh of UPMC • Pittsburgh, PA
This activity has been approved for AHA PPA Category 1 Credibility® • The University of Pittsburgh is an approved activity, as an opportunity institution.
Learn more at www.chp.edu/masterclass
Led by Conference Chairs Aimee Armstrong, MD, and Gregor Krings, MD, the conference will feature hands-on work stations and live cases. Experts in congenital cardiology and cardiac surgery will give inspiring talks on the complementary role of 3D imaging (3DRA, TEE, ICE, CT, MRI) for interventional catheterization and surgery.

**Topics**
- Multimodality 3D imaging for CHD intervention and surgery
- Airway imaging with 3DRA
- 3DRA for aortic disease, PPS, PPVI and single ventricle heart disease

**Audience**
The course is designed for pediatric and adult congenital cardiologists, cardiac surgeons, radiologists, nurses and techs who work in the cath lab, echo or MRI.

**Abstracts**
Abstract deadline is September 1, 2016. Acceptance notifications will be made by September 15, 2016.

Visit [3DRA.org](http://3DRA.org) to learn more or to register.
Tuesday’s sessions were highlighted by several talks on neurologic and behavioral problems, including a hands-on demonstration by chiropractor Dr. Tommy John III on how improving movement can help overcome some of the physical limitations imposed by the syndrome. The afternoon session included a lively panel discussion on potential gene-based therapies for intellectual disability and autism, with the hopes of launching at least one pilot clinical trial by the end of 2016. The day culminated by attending the San Diego Padres game that evening, with tickets graciously donated for all of the families by the Padres.

Wednesday began with a comprehensive overview of endocrine problems that can occur in JS, followed by a number of breakout sessions led mostly by family members of affected children. Perhaps the highlight and most moving session of the conference was the Wednesday afternoon panel discussion consisting of adults with JS, as they fielded questions about what it is like to live with JS.

The remainder of the afternoon consisted of more breakout sessions, including another gripping discussion led by Reverend Sey entitled, “Shut Up About Your Perfect Child.”

Thursday, the final day of the conference, was highlighted by an interactive music therapy session organized by Dr. Barbara Reuer and three of her music therapists (www.resoundingjoyinc.org). The emphasis was on participation, and people of all ages with JS found themselves engaged and thoroughly enjoying the moment. The conference concluded with a picnic in which families had one final opportunity to say goodbye to each other until the next conference, tentatively scheduled for the summer of 2018.

Numerous on-site assessments took place during the conference, including: cognitive and behavioral, three-dimensional craniofacial imaging, physical exams, and one-on-one family meetings with me. These assessments have been instrumental in acquiring new knowledge, ultimately leading to improved therapies for people with JS.

Financial support was provided, in part, by the Jeffrey Modell Foundation (www.jmworld.com), Vivint Gives Back (www.vivint.com/company/gives-back), and the UCSD Department of Pediatrics (www.pediatrics.ucsd.edu). The Sulpizio family kindly donated Magali wine for all of the speakers. In addition, many families did their own fundraising to afford the cost of attending the conference, and thanks to some generous anonymous donors, limited scholarships were made available to families in financial need. In one case the father of a child from England, who sold his guitar in order to afford the costs of bringing his family to the conference, was given a brand new handmade guitar graciously provided by Pepe Romero Jr., of the famous Romeros family of classical guitarists.

Ironically, it was my interest in the broken hearts of people with JS that initially got me involved with this remarkable group of families. To that end, we have made some exciting strides in identifying the gene that causes congenital heart defects in JS, a second genetic locus that can prevent heart defects in mice lacking the gene that causes heart defects, and most recently an animal model for HLHS using the commonly studied frog Xenopus. Despite these very gratifying successes, I never anticipated that 20 years after seeing my first JS patient, it would be the strength and beauty of their hearts that 20 years after seeing my first JS patient, it would be the strength and beauty of their hearts that could teach me so much about the human condition, and why I remain involved with this unique and extraordinary group of families.

CONGENITAL CARDIOLOGY TODAY
© 2016 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.
www.CongenitalCardiologyToday.com

Company offices:
11502 Elk Horn Dr.
Clarkeburg, MD 20871 USA

Editorial offices:
16 Cove Rd, Ste 200
Westerly, RI 02891 USA

Publishing Management:
• Tony Carlson, Founder, President & Sr. Editor - TCarlsonmd@gmail.com
• Richard Koulbanis, Group Publisher & Editor-in-Chief - RichardK@CCT.bz
• John W. Moore, MD, MPH, Group Medical Editor - JMoore@RCHSD.org
• Allan Berthe, Contributing Editor-Special Projects

Editorial Board:
Teiji Akagi, MD; Zohair Al Halees, MD; Mazen Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lamberti, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

Free Subscription to Qualified Professionals: Send your name, title(s), hospital or practice name, work address and url, phone, fax and email to: sub@cct.bz.

Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.
Join Our Team

Career opportunities at the Pediatric Heart Center in Long Beach, California, part of the Memorial Healthcare System - Miller Children’s and Women’s Hospital. Join a team of three board certified pediatric cardiologists who provide an array of comprehensive services. This busy practice in Orange, San Diego and Riverside Counties with a large outpatient volume covers a number of outreach offices and is currently expanding into the Long Beach/South Bay area.

Medical Director - Interventional Pediatric Cardiologist

- Lead the program and support the hospital’s strategic vision for the Pediatric Heart Center.
- Work collaboratively with the hospital’s cardiac surgeon to develop and promote the premier program at Miller Children’s and Women’s Hospital throughout Southern California.

Requirements:
- Leadership experience in a nationally recognized congenital heart center and/or large tertiary children’s hospital
- Previous experience and vision in planning, building and executing the development of a state-of-the-art congenital cardiac cath lab, working with a cardiac ICU
- Ability to assist the PICU team in the development of a new CVICU
- Help with program growth in collaboration with key hospital and practice leadership
- Program development and fundraising experience
- Board certified interventional pediatric cardiologist

Medical Director - Non Invasive Imaging

Requirements:
- Expertise and experience in clinical imaging, research and teaching
- Leadership experience to serve as director of the non-invasive imaging program
- Ability to work closely with the Heart Center and hospital leadership to lead program development and expansion.
- Board certified pediatric cardiologist

BENEFITS:

- Located in desirable Southern California
- Competitive salary and excellent benefits including health/dental/vision, 401(k), annual CME allowance, employee stock purchase plan, professional liability insurance, and assistance with mandatory hospital credentialing and state licensing

For more information:
- Visit pediatrix.com/clinicalcareers
- Call 800.243.3839, ext. 5589
- Email janet_friedman@mednax.com

Pediatric Medical Group is a division of MEDNAX, an Equal Opportunity Employer
OPENING DOORS TO THE FUTURE

CP Stent™
For Coarctation of the Aorta

INDICATIONS FOR USE: The Covered CP Stent is indicated for use in the treatment of native and/or recurrent coarctation of the aorta involving the aortic isthmus or first segment of the descending aorta where there is adequate size and patency of at least one femoral artery associated with one or more of the following: Acute or chronic wall injury; Nearly atretic descending aorta of 3 mm or less in diameter; A non-compliant stenotic aortic segment found on pre-stent balloon dilation; A genetic or congenital syndrome associated with aortic wall weakening or ascending aortic aneurysm.

WARNINGS/PRECAUTIONS: Coarctation of the aorta involving the aortic isthmus or first segment of the descending aorta should be confirmed by diagnostic imaging. The CP stent has not been evaluated in patients weighing less than 20kg. As with any type of implant, infection secondary to contamination of the stent may lead to aortic regression or aneurysm formation. Crimping the stent on a balloon catheter smaller than 12mm may cause damage to the stent. Excessive handling and manipulation of the covering while crimping the stent may cause the covering to tear off of the stent. This device is intended for single use only. Do not resterilize and/or reused, as this can potentially result in compromised device performance and increased risk of cross-contamination.

CONTRAINDICATIONS: Patients too small to allow safe delivery of the stent without compromise to the systemic artery used for delivery. Unfavorable aortic anatomy that does not dilate with high pressure balloon angioplasty. Curved vasculature. Occlusion or obstruction of systemic artery precluding delivery of the stent. Clinical or biological signs of infection. Active endocarditis. Known allergy to aspirin, other antiplatelet agents, or heparin. Pregnancy.

Reference the IFU for a complete listing of indications, contraindications, warnings and precautions. www.bisusa.org

Rx only CV9048-5/16 @2016 B. Braun Interventional Systems Inc. CP Stent™ is a trademark of NuMED, Inc.

Distributed by:
B. Braun Interventional Systems Inc.
Bethlehem, PA 18018 | USA
Tel: 877-836-2228 Fax: 610-849-1334
www.bisusa.org